One of the main points of focus for analysts at an R&D briefing by Sumitomo Dainippon Pharma Co. Ltd. (SDP) in Japan last month was an innovative molecule for schizophrenia developed by the Japanese firm’s US affiliate Sunovion Pharmaceuticals Inc. and now moving through late pivotal trials.
New clinical data have just been published for the first-in-class drug, whose new mode of action may overcome some of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
